Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Acute Myelogenous Leukemia
Drug:
cytarabine
(
DNA synthesis inhibitor
,
DNA-directed DNAP inhibitor
) +
clofarabine
(
DNA synthesis inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Acute Myeloid Leukemia (Age >/=18 years)...THERAPY FOR RELAPSED/REFRACTORY DISEASE...Aggressive therapy for appropriate patients...Clofarabine +/- Cytarabine +/- idarubicin
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.